CHINOOK THERAPEUTICS INC's ticker is KDNY and the CUSIP is 16961L106. A total of 152 filers reported holding CHINOOK THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $4,167,187 | +46.5% | 108,464 | -11.7% | 0.00% | 0.0% |
| Q1 2023 | $2,844,696 | -79.1% | 122,881 | -76.3% | 0.00% | -66.7% |
| Q4 2022 | $13,610,035 | +39.3% | 519,467 | +4.6% | 0.00% | +50.0% |
| Q3 2022 | $9,768,000 | +32.3% | 496,819 | +17.7% | 0.00% | 0.0% |
| Q2 2022 | $7,385,000 | +641.5% | 422,251 | +593.9% | 0.00% | – |
| Q1 2022 | $996,000 | +390.6% | 60,849 | +389.6% | 0.00% | – |
| Q4 2021 | $203,000 | -89.5% | 12,428 | -91.8% | 0.00% | – |
| Q3 2021 | $1,942,000 | -53.8% | 152,183 | -48.8% | 0.00% | -100.0% |
| Q2 2021 | $4,200,000 | -50.8% | 297,422 | -46.1% | 0.00% | -50.0% |
| Q1 2021 | $8,528,000 | -4.8% | 551,756 | -2.3% | 0.00% | 0.0% |
| Q4 2020 | $8,960,000 | – | 564,898 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 5,161,888 | $119,497,707 | 24.70% |
| Saturn V Capital Management LP | 506,818 | $11,732,837 | 8.76% |
| Octagon Capital Advisors LP | 2,551,703 | $59,071,924 | 8.50% |
| Affinity Asset Advisors, LLC | 976,021 | $22,594,886 | 7.46% |
| Frazier Life Sciences Management, L.P. | 4,345,559 | $100,599,691 | 7.28% |
| Altium Capital Management LP | 305,000 | $7,060,750 | 3.92% |
| Deep Track Capital, LP | 3,000,000 | $69,450,000 | 2.85% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 319,989 | $7,407,745 | 2.07% |
| Nan Fung Group Holdings Ltd | 113,950 | $2,637,943 | 1.80% |
| Nicholas Investment Partners, LP | 972,191 | $22,506,222 | 1.71% |